by Angus Reid | April 11, 2021 9:30 pm
April 12, 2021 – Weeks of questions, blood clot concerns and changing guidance over who should receive the AstraZeneca vaccine has had a devastating impact on Canadian confidence in it.
New public opinion data from the non-profit Angus Reid Institute finds just 41 per cent of Canadians who are yet unvaccinated – but intend to be – are comfortable with receiving an AZ vaccine, currently comprising about 20 per cent of Canada’s stockpile.
The survey’s findings show that while urgency to be inoculated against COVID-19 climbs again to an all time high, critical doubts about one of the main brands that make up this country’s vaccine program could result in Canadians opting not to be vaccinated at all if a dose of AstraZeneca were the only option on offer.
Nearly one-quarter (23%) of those who haven’t yet received a vaccine but intend to say they would reject a dose from AstraZeneca outright if that is the brand being administered to them.
Levels of discomfort increase considerably among women over the age of 34, two-in-five of whom say they are ‘extremely uncomfortable’ with the idea of receiving the AstraZeneca dose.
Against the backdrop of these doubts, public health officials and politicians must also battle skepticism over another critical aspect of COVID-19 related data: the very number of people who have been infected. Fully one-in-five people in this country believe the federal government has been inflating COVID-19 statistics, that the real figures are lower, while fewer than a third think the official data is accurate (32%).
More Key Findings:
The Angus Reid Institute (ARI) was founded in October 2014 by pollster and sociologist, Dr. Angus Reid. ARI is a national, not-for-profit, non-partisan public opinion research foundation established to advance education by commissioning, conducting and disseminating to the public accessible and impartial statistical data, research and policy analysis on economics, political science, philanthropy, public administration, domestic and international affairs and other socio-economic issues of importance to Canada and its world.
As Canadians endure a third wave of the COVID-19 pandemic, spurred on by highly infectious variants of the virus – B117 originating in the UK, P1 from Brazil, and B1351 from South Africa – all eyes are on the coast-to-coast mass vaccination program. Positive news for public health officials finds Canadians feeling ever more urgency to receive their jab. If 2020 was characterized by hesitancy surrounding the potential inoculation, public opinion now trends in favour of being inoculated, as soon as possible:
*Includes both those who want vaccine immediately and those who have already had at least one dose
To date, approximately 18 per cent of Canadians have had at least one dose of a COVID-19 vaccine. This survey, notably, yielded exactly 18 per cent of respondents stating that they had been vaccinated (see detailed tables). Among them, the experience has been largely positive. Nine-in-ten (87%) had a very good experience, while 11 per cent said it was just okay:
While experiences have been good and willingness to receive a vaccine is trending upward, a troubling undercurrent is emerging around significant discomfort with one of the vaccines on offer: AstraZeneca.
To recap, Health Canada recently changed the label on that vaccine after “very rare reports of blood clots associated with low levels of blood platelets.” Public health officials say the vaccine remains safe and that the benefits heavily outweigh the risks, but countries around the world have paused delivery or set age limits on usage such that younger individuals do not receive it. Canada stopped administering the vaccine to people under the age of 55 at the end of March.
AstraZeneca itself, and the version manufactured by the Serum Institute of India, called COVISHIELD, make up just under 20 per cent of total vaccines distributed in Canada thus far.
Canadians who have not received a vaccine but are planning to are far more comfortable with doses manufactured by Pfizer and Moderna than they are with AstraZeneca’s offering and that of the forthcoming Johnson and Johnson vaccine (scheduled to arrive in Canada in the coming weeks). Far and away however, AstraZeneca is the vaccine that prompts the most discomfort among Canadians:
Levels of comfort receiving the AstraZeneca vaccine are much lower among female respondents than males, with two-in-five women over the age of 35 saying they are extremely uncomfortable being offered that vaccine:
Among those uncomfortable with AstraZeneca, two-in-five say they that if they were offered that brand of vaccine, they would reject it. Importantly, another 31 per cent among this group say they don’t know what they would do:
Among those who express discomfort towards any of the vaccines being (or soon to be) administered in Canada, younger people are much more willing to overcome their worries and take the jab anyway, while those over the age of 54 are more hesitant to be receive a dose of a vaccine in which they are not fully comfortable:
Another potential source of discomfort is the timeline between first and second doses of the vaccine. Several provinces in Canada have lengthened this period beyond what the manufacturers recommend.
Public health officials continue to assure Canadians that this is safe and that allowing more people to receive at least one dose sooner means some protection is better than none at all for a bigger group. Critics, however, argue that there is not enough information about how much protection the vaccines provide against COVID-19 after just the first dose to guarantee the safety of this decision.
For their part, Canadians would largely prefer that the original guidance with a shorter time period between doses be maintained. This is the case for at least 62 per cent of resident in every region:
Canada passed a grim milestone in early April as the nation confirmed its one millionth case of COVID-19. Canadians are fairly certain the official number should be much higher.
Indeed, three per cent of respondents to this survey say that they have had a confirmed positive test for the virus; this is right in line with the nationally report number. That said, four-times as many say that they think they have been sick with COVID-19 (12%) while another 8 per cent would not rule it out:
Albertans and Ontarians are most likely to say that they have or may have been ill with COVID-19, while at least 15 per cent in every region express this uncertainty. Canadians over the age of 54 are least likely to think that they have contracted COVID-19 (see detailed tables):
The government of Canada regularly reports on positive cases as communicated by health authorities across the country. This likely does not capture the number of total cases, given the asymptomatic nature of some experiences, and the mild symptoms felt by many. While only one-in-three Canadians feel that the number of cases reported is accurate, a significant segment, nearly one-in-five (21%) are skeptical and believe the number has been inflated. A greater number (33%) say that it is likely too low:
In most of the country two-thirds of Canadians say that the reported number is either correct or too low. In Alberta, however, residents are notably more likely to say that it is too high:
There is also evidently a political element to data reporting. Past Liberal and New Democratic Party voters are more likely than the national average to say that reports undercount the number of COVID-19 cases, while past Conservative and Bloc Quebecois voters are more likely to say the numbers reported are inflated:
Canada’s rollout of COVID-19 vaccinations has sped up considerably in recent weeks. After a slow start, characterized by months of delay and ensuing frustration, more than 10 million doses have now been distributed to the provinces by the federal government. Despite this, however, there are still concerns about whether the federal government has procured sufficient doses for everyone who wants a jab to receive one in a timely fashion.
The graph below shows the percentage of Canadians saying the government has done a good job in securing sufficient doses of the vaccine, plotted alongside the total number of doses distributed to the provinces and territories. Much of this continuing criticism may owe to the fact that the United States is well ahead of Canada in its vaccination progress:
Looking at these data in full, at least 55 per cent of Canadians have been critical of the government on this question since early February:
The good news for federal officials is that confidence in the government to manage procurement and distribution has increased slightly to nearly an even divide. More than two-in-five (45%) say that they are confident in the Liberals while half (50%) disagree:
While the federal government plays a significant role in procurement, the operation of taking delivery of vaccine and ultimately jabbing them into the arms of Canadians is largely left to provincial health authorities. This has led to tension in recent days as Prime Minister Trudeau urged provinces to speed up delivery with the nation’s stockpile increasing each week. As of April 9th, most regions have delivered doses at a relatively similar rate, with Atlantic Canada having given out the fewest per capita doses and Saskatchewan the most:
In terms of overall provincial performance on this key issue, the governments of Quebec, the Atlantic provinces, and Saskatchewan, earn the most praise from their respective constituents; at least three-in-five say their governments have done a good job in handling distribution. By contrast, only one-in-three in Manitoba and Ontario feel this way:
For detailed results by age, gender, region, education, and other demographics, click here.
For questionnaire, click here.
To read the full report, including detailed tables and methodology, click here.
Shachi Kurl, Executive Director: 604.908.1693 firstname.lastname@example.org @shachikurl
Dave Korzinski, Research Director: 250.899.0821 email@example.com
Source URL: https://angusreid.org/astrazeneca-confidence/
Copyright ©2021 Angus Reid Institute unless otherwise noted.